After a desperate, deadly year of coronavirus, the UK's vaccination programme has delivered first doses to 15 million of the oldest and most vulnerable.
Every vaccine bought for the UK has been on the assumption that just 30 million people - less than half the population - will get it.
Two COVID-19 vaccines being tested in the UK have moved on to the third phase of trials, marking a significant step forward in the development process.
A low-cost, widely used anti-inflammatory drug improved survival in patients with Covid-19, the first treatment to show life-saving promise months into the pandemic.
Professor Peter Horby, Professor of Emerging Infectious Diseases and Global Health, has said that dexamethasone is the 'only drug shown to reduce mortality'.
Around 90% of experimental vaccines never reach the clinic because of problems in development or manufacture.